We view a successful team as one that consists of tenacious individuals who think strategically, act boldly, and doggedly challenge old assumptions with fresh ideas.
With the support of our dynamic Executive Management and Key Executives Team, our Investment Banking Team is a powerful combination of talent, experience and synergy that has a firm wide commitment to customer service. They propel new visions forward with a keen sense of direction and purpose, having access to the resources, experience and conviction to go there with confidence.
Marta Wypych
Head of Investment Banking
Marta is a seasoned investment banker with 15+ years of investment banking experience. Previously she was a Managing Director of Investment Banking for HRA Capital where she oversaw operational activities related to transaction execution, processing, and settlement and advised clients on placement process, investment banking M&A, relevant compliance activities, and regulatory requirements. Prior to joining HRA, Ms. Wypych was a Senior Vice President at Rodman and Renshaw, LLC where she bridged communications across various business units to establish strategic programs that increased institutional investors’ access to corporate management. Ms. Wypych holds a Bachelor of Science in Corporate Finance and Masters of Science in Management and Marketing from Nicolaus Copernicus University and holds FINRA Series 7, 24, 63, and 79 licenses.
Donald A. Wojnowski
Senior Managing Director of Investment Banking
As Senior Managing Director of Investment Banking at Paulson, Donald brings a wealth of knowledge and expertise to the table with a main focus on healthcare and special situations investment banking. He has over 40 years of senior management and investment banking experience in the securities industry. Before joining Paulson in 2016, Donald ran several small and successful boutique investment banks and now heads Paulson’s Healthcare Investment Banking team. His track record speaks for itself, showcasing his ability to navigate complex financial landscapes with precision and expertise, and his leadership and deep skillset help to ensure that Paulson remains at the forefront of financial innovation and strategic investments. He currently holds FINRA Series 3, 7, 24, 63, 66 and 79 licenses.
Jainal Bhuiyan
Senior Managing Director
As Senior Managing Director at Paulson, Jainal brings deep healthcare and value investing experience. He was formerly a partner at HRA Capital, a healthcare merchant investment bank. He is currently Chairman of the Board of FundRx, a healthcare venture investment platform. Prior to joining HRA Capital, he was a Senior Vice President of healthcare investment banking at Rodman & Renshaw, where he was also Head of Healthcare Equity Capital Markets. Early in his career, he worked as a Senior Analyst at Provident Healthcare Partners, a Boston-based boutique M&A shop focused on healthcare services. Prior to Provident he worked as a Management Analyst with BearingPoint, consulting to the Department of Defense. Mr. Bhuiyan has a Bachelor of Science degree from Cornell University’s Charles H. Dyson School of Applied Economics and Management. He currently holds FINRA Series 7, Series 63 and Series 79 licenses.
Cameron Gray
Senior Investment Banker
Cameron is a seasoned investment banker with over ten years of investment banking experience with firms including MDB Capital, B. Riley Financial, and National Securities. His past deals include Second Sight Medical Products, Cue Biopharma, Provention Bio, Viewpoint Molecular Targeting, and iTolerance Inc. and he currently sits on the Board of Directors of Cue Biopharma, Viewpoint Molecular Targeting, and iTolerance Inc. Prior to his investment banking career, Dr. Gray served as Chief Executive Officer and a member of the board of directors of Endeavor IP, Inc., an intellectual property services and patent licensing company. Prior to that, he was a Senior Vice President at ICAP Patent Brokerage, LLC, where he managed its life sciences and Asia Pacific businesses. Dr. Gray has a J.D. from George Washington University School of Law, a Ph.D. in biophysics from the University of Virginia, and a B.A. in physics from Princeton University and holds FINRA Series 7, 63, and 79 licenses.
Elizabeth Burk
Investment Banking Analyst
Elizabeth is currently an Investment Banking Analyst with Paulson. Prior to joining the Paulson Investment Banking team in 2022, she spent three years researching antibiotic resistance bacteria for the School of Medicine at the University of Southern California. There she primarily focused on developing monoclonal antibodies and completing an FDA study that outlined optimal laboratory murine conditions to mimic hospital derived infections. She has been published as a co-author in American Society for Microbiology: Infection and Immunity and has two additional manuscripts pending publication. Elizabeth is a graduate of Johns Hopkins University where she received a Bachelor of Art in Biology and holds a FINRA Series 7 license.